Literature DB >> 116294

Amphetamine psychosis and psychotic symptoms.

D S Janowsky, C Risch.   

Abstract

Amphetamine psychosis has been considered to be a pharmacologic model of schizophrenia. Fifteen previously reported cases were reviewed in which experimental induction of amphetamine psychosis occurred in nonschizophrenic drug abusers. Seven (possibly ten) cases manifested Schneider's first rank symptoms and all had World Health Organization Present-State Exam symptoms which discriminated schizophrenia. This observation draws further parallels between the phenomenology of amphetamine psychosis and schizophrenic symptoms.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 116294     DOI： 10.1007/bf00491982

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  15 in total

1.  COMPARISON OF AMPHETAMINE PSYCHOSIS AND SCHIZOPHRENIA.

Authors:  D S BELL
Journal:  Br J Psychiatry       Date:  1965-08       Impact factor: 9.319

2.  Dextroamphetamine. Evaluation of psychomimetic properties in man.

Authors:  J D Griffith; J Cavanaugh; J Held; J A Oates
Journal:  Arch Gen Psychiatry       Date:  1972-02

3.  The phenomenology of experimentally induced amphetamine psychosis--preliminary observations.

Authors:  B M Angrist; S Gershon
Journal:  Biol Psychiatry       Date:  1970-04       Impact factor: 13.382

4.  First rank symptoms of schizophrenia. I. The frequnncy in schizophrenics on admission to hospital. II. Differences between individual first rank symptoms.

Authors:  C S Mellor
Journal:  Br J Psychiatry       Date:  1970-07       Impact factor: 9.319

5.  A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosis.

Authors:  L E Jönsson; K Sjöström
Journal:  Br J Psychiatry       Date:  1970-12       Impact factor: 9.319

6.  Schneiderian first-rank symptoms and clinical prognostic features in schizophrenia.

Authors:  M A Taylor
Journal:  Arch Gen Psychiatry       Date:  1972-01

7.  "Psychedelic" experiences in acute psychoses.

Authors:  M B Bowers; D X Freedman
Journal:  Arch Gen Psychiatry       Date:  1966-09

8.  Reactive psychoses and schizophrenia with good prognosis.

Authors:  M S McCabe
Journal:  Arch Gen Psychiatry       Date:  1976-05

9.  The diagnosis and understanding of schizophrenia. Part I. Use of signs and symptoms for the identification of schizophrenic patients.

Authors:  W T Carpenter; J S Strauss; J J Bartko
Journal:  Schizophr Bull       Date:  1974       Impact factor: 9.306

10.  Cross-cultural evaluation of Schneider's first-rank symptoms of schizophrenia: a report from the International Pilot Study of Schizophrenia.

Authors:  W T Carpenter; J S Strauss
Journal:  Am J Psychiatry       Date:  1974-06       Impact factor: 18.112
View more
  29 in total

1.  Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo.

Authors:  J Amiel Rosenkranz; Anthony A Grace
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

Review 2.  Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.

Authors:  Tong H Lee; Steven T Szabo; J Corey Fowler; Paolo Mannelli; O Barry Mangum; Wayne F Beyer; Ashwin Patkar; William C Wetsel
Journal:  Drug Alcohol Depend       Date:  2012-02-21       Impact factor: 4.492

3.  A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.

Authors:  Daniel Wagner; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Martin Hellmich; Joerg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-27       Impact factor: 4.530

4.  Specific opioid-amphetamine interactions in the caudate putamen.

Authors:  S K Woo; R J Hitzemann; H H Loh
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 5.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Perseverative behaviour after amphetamine; dissociation of response tendency from reward association.

Authors:  R M Ridley; H F Baker; T A Haystead
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

8.  Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?

Authors:  Mariana Bendlin Calzavara; Wladimir Agostini Medrano; Raquel Levin; Sonia Regina Kameda; Monica Levy Andersen; Sergio Tufik; Regina Helena Silva; Roberto Frussa-Filho; Vanessa Costhek Abílio
Journal:  Schizophr Bull       Date:  2008-02-16       Impact factor: 9.306

9.  Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90).

Authors:  Icro Maremmani; Pier Paolo Pani; Matteo Pacini; Jacopo V Bizzarri; Emanuela Trogu; Angelo Gi Maremmani; Gilberto Gerra; Giulio Perugi; Liliana Dell'Osso
Journal:  Ann Gen Psychiatry       Date:  2010-04-13       Impact factor: 3.455

Review 10.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.